Oxford Biomedica (LON:OXB) Announces Quarterly Earnings Results

Oxford Biomedica (LON:OXB) posted its earnings results on Wednesday. The biopharmaceutical company reported GBX (41.75) (($0.54)) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%.

Oxford Biomedica Stock Performance

Shares of Oxford Biomedica stock opened at GBX 273.50 ($3.55) on Friday. Oxford Biomedica has a 1 year low of GBX 187.83 ($2.44) and a 1 year high of GBX 455 ($5.91). The firm’s 50-day moving average is GBX 319.38 and its 200 day moving average is GBX 379.08. The stock has a market cap of £290.73 million, a price-to-earnings ratio of -2.03 and a beta of 1.09. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.